Effect of ischaemia on somatosensory evoked potentials in diabetic patients

TOMAS LOPEZ-ALBURQUERQUE, ANGEL GARCIA MIGUEL, JUAN-JOSE RUIZ EZQUERRO, JOSE DE PORTUGAL ALVAREZ

From the Department of Internal Medicine, the Division of Neurology, Hospital Clinico Universitario, Salamanca, Spain

SUMMARY The nerve action potential at the elbow and somatosensory evoked potentials (SEPs) at the scalp were recorded over 30 minutes of tourniquet-induced limb ischaemia in 10 diabetic patients and 10 controls. According to the SEP changes, an increased resistance to nerve ischaemia in diabetic patients was observed. The pathways involved in SEP conduction are discussed.

It has been reported that diabetic patients retain their vibratory perception much longer than normal individuals during ischaemia.1 This phenomenon has later been demonstrated for touch and pain as well.2 Electrophysiological studies have shown abnormal preservation of the nerve action potential (NAP) after 30 minutes of ischaemia in diabetic patients.3–6 However, the simultaneous changes in the NAP and somatosensory evoked potentials (SEPs) during ischaemia has not yet been investigated in patients with diabetes mellitus. The aim of the present report was to evaluate these changes in a group of diabetic patients.

Patients and methods

The studies were carried out on 10 diabetic patients, aged 18 to 54 years (mean, 36 years), with informed consent, and 10 healthy volunteers, aged 22 to 49 years (mean, 33 years). Six patients were insulin-dependent diabetics and four non insulin-dependent diabetics. Mean duration of diabetes was 4.5 years (range 4 months to 7 years). Clinical or electrophysiological signs of polyneuropathy were detected in seven patients. A sphygmanometer cuff (14 cm wide) was placed on the right arm with its distal border about 5 cm above the antecubital fossa, and was inflated to 80 mm Hg above systolic blood pressure.

Sensory examination (light touch, pinprick, two-point discrimination, joint sense and vibration), the NAPs at the elbow and SEPs at the scalp overlying the contralateral parietal cortex were recorded every 5 minutes for 30 minutes of induced limb ischaemia and for another 30 minutes after release of the cuff. Two saline soaked felt pad electrodes (1-1 cm apart) (Medelec EL 210M) and two Ag/AgCl disk electrodes (1 cm of diameter) were used to record NAPs and SEPs, respectively. The recording electrode for SEPs was placed at C3 (2 cm behind Cz) (International 10–20 system), referenced to a midfrontal electrode (Fz). A two-channel Medelec MS6 electromyograph was used. The right median nerve was percutaneously stimulated at the wrist with an intensity sufficient to elicit a visible twitch in thenar muscles. Stimuli (square waves of 0.2 ms) were delivered at a rate of 5 Hz. The number of responses averaged was 128. The time analysed was 100 ms. Filter setting of 3.2–3200 Hz were used. NAP latency was measured at the first positive peak. Amplitudes were measured peak-to-peak (N19/P22 for the N19 component) and expressed as the percentage value of the pre-ischaemic determination. For statistical evaluation of the results Student’s t test and linear correlations were applied.

Results

(1) Control group

In all normal subjects the following baseline SEP components could be identified: N19, P22, N32, P42 and N58 (fig 1). A pre-ischaemic NAP at the elbow was recorded in the 10 controls.

The amplitudes of the NAP and SEP components tended to decrease as a function of the duration of ischaemia (fig 1). Although the NAP decreased more rapidly than N19 between 10 and 20 minutes, in all 10 controls both potentials were abolished before 30 minutes had elapsed (fig 2). Loss of the NAP, N19 component and proprioceptive sensation occurred simultaneously in eight out of 10 subjects (fig 1). The later components of the SEP were more resistant to ischaemia. When these could no longer be recorded,
Effect of ischaemia on somatosensory evoked potentials in diabetic patients

**Fig 1** The SEP and NAP in one diabetic and a control. The persistence of both SEP and NAP over 30 minutes of ischaemia in diabetic can be observed.

**Fig 2** Changes in amplitude of the NAP and N19 component in controls and diabetics during and after 30 minutes of ischaemia (mean ± SEM).
complete sensory loss appeared. A rapid recovery of the amplitudes took place early in the course of the post-ischaemic period (fig 2).

All SEP peaks and the NAP presented a progressive increase in latency during ischaemia (fig 3). Absolute values of the NAP and N19 latencies are shown in table 1. The decreased absolute mean latency of the NAP at 20 minutes with respect to the mean value obtained at 15 minutes was due to the abolishing of the potential in the subjects with longer baseline latencies. The pre-ischaemic mean values of these latter subjects were significantly higher than those of the patients retaining the NAP at 20 minutes: 3.7 ± 0.4 and 3.3 ± 0.1 ms (SD), respectively (p < 0.05). A correlation between wrist-elbow distances and NAP latencies was observed (r = 0.78) (p < 0.01). When the mean increments in latency of the NAP and N19 were compared, a statistically significant difference was observed from the beginning of ischaemia (p < 0.001) (fig 4). Except for the N58 component, there was no significant difference between delayed latencies of the remaining SEP peaks.

(2) Diabetic patients

In the 10 diabetics, the NAP disappeared only in one (insulin-dependent diabetic of 4 months of evolution) before the end of 30 minutes of ischaemia (at 20 minutes). In this patient, all SEP components were recorded at 25 minutes, after which the test had to be suspended owing to severe pain. In the remaining diabetic patients, the NAP and SEP could be recorded through the test (fig 1).

The decreased amplitude of the NAP and N19 component is shown in fig 2. The NAP amplitude was reduced by 77.7% at 30 minutes. In contrast, minimal changes were observed in N19 and the remaining SEP components.

As in the control group, a significant difference (p
Effect of ischaemia on somatosensory evoked potentials in diabetic patients

![Graph showing delayed latencies of NAP and N19 peak in controls and diabetics during and after 30 minutes of ischaemia (mean ± SEM).](image)

Fig 4  Delayed latencies of the NAP and N19 peak in controls and diabetics during and after 30 minutes of ischaemia (mean ± SEM).

Table 2  Latencies of the nerve action potential (NAP) and N19 peak during ischaemia in diabetics (Mean ± SEM)

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>NAP Absolute values (ms)</th>
<th>Increase (%)</th>
<th>N*</th>
<th>N19 Absolute values (ms)</th>
<th>Increase (%)</th>
<th>N*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>3.7 ± 0.1</td>
<td>—</td>
<td>10</td>
<td>19.8 ± 0.4</td>
<td>—</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>3.8 ± 0.1</td>
<td>44 ± 0.5</td>
<td>10</td>
<td>20.3 ± 0.4</td>
<td>2.4 ± 0.3</td>
<td>10</td>
</tr>
<tr>
<td>10</td>
<td>4.0 ± 0.1</td>
<td>9.7 ± 0.9</td>
<td>10</td>
<td>20.6 ± 0.4</td>
<td>2.4 ± 0.3</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td>4.2 ± 0.2</td>
<td>15.6 ± 1.2</td>
<td>10</td>
<td>21.3 ± 0.4</td>
<td>7.7 ± 0.8</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>4.4 ± 0.2</td>
<td>20.7 ± 2.0</td>
<td>9</td>
<td>22.0 ± 0.4</td>
<td>11.2 ± 0.9</td>
<td>10</td>
</tr>
<tr>
<td>25</td>
<td>4.7 ± 0.2</td>
<td>29.3 ± 3.1</td>
<td>9</td>
<td>22.9 ± 0.3</td>
<td>15.2 ± 1.4</td>
<td>9</td>
</tr>
<tr>
<td>30</td>
<td>5.1 ± 0.2</td>
<td>40.1 ± 4.5</td>
<td>9</td>
<td>23.5 ± 0.3</td>
<td>21.1 ± 2.0</td>
<td>9</td>
</tr>
</tbody>
</table>

*Number of the patients in whom the potential could be recorded.

< 0.001) between the NAP and N19 delayed latencies was observed (figs 3 and 4). The absolute values of the NAP and N19 component during ischaemia are summarised in table 2. There was no statistically significant difference between delayed latencies of the different SEP peaks (fig 3).

During the first 20 minutes of ischaemia, the increments in latency of the NAP were similar in the diabetics and controls (fig 4). However, from 5 minutes of ischaemia the N19 peak latencies of the diabetic patients were significantly less delayed than those of the control group (p < 0.001) (fig 4).

Discussion

We have observed the existence of an abnormal resistance to ischaemia in diabetic nerves, since in nine out of the 10 diabetic patients studied both the NAP and SEP could still be recorded at 30 minutes. In contrast, all normal subjects lost these potentials before this time.

In controls, the percentage attenuation of the N19 amplitude tended to decrease at a slower rate than that of the NAP. However, both these potentials and proprioceptive sensation disappeared simultaneously in eight subjects. Similar results have been reported previously, suggesting that the N19 component may be carried by large myelinated fibres considered to be the most sensitive to ischaemia. The SEP of longer latencies disappeared later. This greater resistance to ischaemia suggest that their conduction may rely on smaller diameter fibres than the N19 component.
ental findings showing a mixed participation (dorsal column/medial lemniscal system and spinothalamic pathway) in SEP conduction.\textsuperscript{11–14} A greater divergence between the N19 and NAP amplitude curves was observed in diabetic patients. Whereas the NAP amplitude was reduced by 77–79\% at 30 minutes of ischaemia, no significant changes were shown by N19 component. Although the slower decrease of N19 amplitude curves than the NAP in diabetics and controls may suggest two different pathways for both potentials, this finding could be explained assuming that the N19 component may be carried by a small number of nerve fibres, owing to integration and amplification of afferent impulses in the CNS.\textsuperscript{15} In contrast, the NAP amplitude depends on the synchronisation of peripheral nerve impulses.\textsuperscript{16,17} This may be the reason why the control subjects with shorter wrist–elbow distances retained the NAP for longer during ischaemia.\textsuperscript{10,18–20}

Similarly, the greater resistance to ischaemia of late components of SEPs observed in our control group could be due to a more synaptic amplification of these waves than N19, allowing the former to be recorded when only a few large fibres are still conducting. This would be an alternative explanation to the dual conduction pathway referred to above, bearing in mind the possibility that the intensity of the stimulus applied to our subjects is probably insufficient to stimulate a large number of small fibres.

It seems that differences in amplitude changes of the NAP and N19 component between diabetics and controls may be one of rapidity and not of degree. In fact, if in diabetics the ischaemic time is prolonged until a point where a peripheral conduction block is achieved, one could expect to obtain a convergence of the NAP and N19 amplitude curves at zero, as in normal subjects.

Unlike amplitude changes, delayed latencies of the NAP and N19 peak during ischaemia suggest different pathways for both these potentials. Indeed, the increase in absolute latency of the N19 peak was greater than the NAP in diabetics and controls (more than 4 times at 20 minutes of ischaemia in these latter). Since the length of pathway made ischaemic was similar for both potentials, a minor difference between their delayed latencies was to be expected. Yamada et al\textsuperscript{8} observed a similar delay for Erb’s potential and N19 latencies during ischaemia. These authors stated that both potentials are primarily carried by large myelinated fibres. Because the first positive peak of the NAP is thought to correspond to the large-diameter fast-conducting fibres,\textsuperscript{21} one could argue from our results that N19 may be subserved by smaller diameter fibres than the NAP, probably by Group II fibres, conducting in the forearm not faster than approximately 75 m/s.\textsuperscript{22} If these two different pathways for both NAP and N19 are assumed, it could be postulated (for linking amplitude and latency changes) that while conduction block in the largest fibres is occurring fairly rapidly the smaller fibres are just being delayed.

Although the conduction changes in ischaemic nerves seem to be due mainly to hypoxia,\textsuperscript{4,10–18} mechanical factors cannot be ruled out.\textsuperscript{23} Unlike the NAP, the N19 pathway was compressed by the tourniquet. This additional factor may contribute to the greater delayed latency of the N19 peak, since, as has been reported,\textsuperscript{23} large nerve fibres are more sensitive to compression than ischaemia. Experimental evidence exists of nerve lesions produced by pneumatic tourniquet compression.\textsuperscript{24} However, the early post-ischaemic recovery and the brief and relatively slight compression applied to the arm of our subjects do not suggest a structural nerve lesion as the main causative factor of the SEP changes.

The NAP latencies of diabetics and controls were similarly delayed. Less delayed latencies in diabetics than controls have been usually reported.\textsuperscript{2–4,6} However, Castaigne et al\textsuperscript{25} found a similar phenomenon to our own in uraemic patients, suggesting the possibility of “a greater influence of ischaemia upon nerve excitability than on nerve conduction”. On the contrary, the N19 latencies of our diabetic patients were significantly less delayed than those of the control group from 5 minutes of ischaemia. This different response to ischaemia of fibres conducting the NAP and N19 component is consistent with the suspicion that the main fibre group determining the latency of the NAP is not the same as that which determines the N19 peak.

In diabetics there was no significant difference between delayed latencies of the N19 and the remaining SEP peaks during ischaemia. In the control group, only the N58 was significantly delayed in relation to the other SEP peaks. This component showed great fluctuations in latency and morphology during ischaemia. Our results contrast with those of Yamada et al\textsuperscript{8} who identified two groups from the latency changes during ischaemia: one formed by Erb’s potential, early SEP and the N19 component, and another composed of the components of longer latency, the increments in latency of this latter group being greater than those of the former. They suggest different pathways for these two groups.

The increased resistance of diabetic nerves to ischaemic conduction block is unknown. It could, however, be related to metabolic control of diabetes.\textsuperscript{26,27} This phenomenon, which is not specific to diabetes mellitus,\textsuperscript{20,25,28–31} is probably the result of many factors.\textsuperscript{32} It may be due to a reduced metabolic need of impulse conduction derived from a slight depolarisation of diabetic nerves secondary to
an abnormal function of the sodium pump caused by a defect in sodium-potassium ATPase.33 The basic abnormality remains unclear. However, an excessive accumulation of sorbitol34 and a reduced myoinositol concentration35 in diabetic nerves seem to be involved.

From the SEP study, the existence may be inferred of an abnormally increased resistance to ischaemia of diabetic nerves, as was to be expected. However, it is difficult to arrive at a firm conclusion about the SEP pathway conduction from our findings, because there is a certain disparity between latency and amplitude changes. It could be due to a difference influence of ischaemia on these two variables. Nevertheless, the latency changes from our diabetic and control groups suggest (if additional compressive factors on SEP pathway are not taken into account) that the N19 component is not mainly carried by the same large myelinated fast-conducting fibres originating the first positive peak of the NAP. On the contrary, the N19 and the following components of the SEP included in approximately the first 45 ms seem to be conducted through the same pathway.

References

28 Christensen NJ, Ørskov H. Vibratory perception during ischaemia in uremic patients and in subjects with mild carbohydrate intolerance. J Neurol Neurosurg...


Effect of ischaemia on somatosensory evoked potentials in diabetic patients.

T López-Alburquerque, A García Miguel, J J Ruiz Ezquerro and J de Portugal Alvarez

J Neurol Neurosurg Psychiatry 1987 50: 428-434
doi: 10.1136/jnnp.50.4.428

Updated information and services can be found at:
http://jnnp.bmj.com/content/50/4/428

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/